Innovation in personalized medicine: BiDil® as a case study for integrating clinical and policy developments

著录项

• 来源
  《Personalized Medicine》 |2006年第4期|421-427|共7页
• 作者

  Amalia M Issa; L Todd Weiss; Waqas Tufail; Kathryn A Phillips; Stephanie L Van Bebber;

  展开▼
• 作者单位

  The Methodist Hospital and University of Houston, Program in Personalized Medicine & Targeted Therapeutics and the Abramson Center for the Future of Health, 300 Technology Building, T2–309, Houston, TX 77204–4021, USA.;

  The Methodist Hospital and University of Houston, Program in Personalized Medicine & Targeted Therapeutics and the Abramson Center for the Future of Health, 300 Technology Building, T2–309, Houston, TX 77204–4021, USA.;

  The Methodist Hospital and University of Houston, Program in Personalized Medicine & Targeted Therapeutics and the Abramson Center for the Future of Health, 300 Technology Building, T2–309, Houston, TX 77204–4021, USA.;

  University of California, Department of Clinical Pharmacy, School of Pharmacy, San Francisco, 521 Parnassus Avenue, C-152 Box 0622, University of California, San Francisco, CA 94143–0622, USA;

  University of California, Department of Clinical Pharmacy, School of Pharmacy, San Francisco, 521 Parnassus Avenue, C-152 Box 0622, University of California, San Francisco, CA 94143–0622, USA;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类
• 关键词

  BiDil®; genotype; health policy; heart failure; hydralazine hydrochloride; isosorbide dinitrate; personalized medicine; pharmacogenomics; phenotypic; race;

  机译：BiDil®;基因型;卫生政策;心脏衰竭;盐酸肼苯哒嗪;硝酸异山梨酯个性化医学;药物基因组学表型种族;